Purpose: Seizures frequently impact the quality of life of patients with low grade tumors. Management is often based on best clinical judgment. We examined factors that correlate with seizure outcome to optimize seizure management. Methods: Patients with supratentorial low-grade tumors evaluated at a single institution were retrospectively reviewed. Using multiple regression analysis the patient characteristics and treatments were correlated with seizure outcome using Engel's classification. Results: Of the 73 patients with low grade tumors and median follow up of 3.8 years (range 1-20 years), 54 (74%) patients had a seizure ever and 46 (63%) had at least one seizure before tumor surgery. The only factor significantly associated with pre-surgical seizures was tumor histology. Of the 54 patients with seizures ever, 25 (46.3%) had a class I outcome at last follow up. There was no difference in seizure outcome between grade II gliomas (astrocytoma grade II, oligodendroglioma grade II, mixed oligoastrocytoma grade II) and other pathologies (pilocytic astrocytoma, ependymomas, DNET, gangliocytoma and ganglioglioma). Once seizures were established seizure prognosis was similar between different pathologies. Chemotherapy (p = 0.03) and radiation therapy (p = 0.02) had a positive effect on seizure outcome. No other parameter including significant tumor growth during the follow up period predicted seizure outcome. Only three patients developed new-onset seizures after tumor surgery that were nonperioperative. Anticonvulsant medication was tapered in 14 patients with seizures and 10 had no further seizures. Five patients underwent additional epilepsy surgery with a class I outcome in four. Two patients received a vagal nerve stimulator with >50% seizure reduction. Discussion: Seizures at presentation are the most important factor associated with continued seizures after tumor surgery. Pathology does not influence seizure outcome. Use of long term prophylactic anticonvulsants is unwarranted. Chemotherapy and radiation therapy have a favorable impact on seizure outcome. Additional epilepsy surgery is effective.
ß 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. were summarized as other pathologies. All patients were examined in the neuro-oncology clinic. Follow-up data with records of surgery, seizure outcome, and tumor outcome were available. All subjects underwent at least one surgical intervention for pathologic diagnosis which was categorized as biopsy, partial resection, or total resection as determined by the neurosurgeon. Electrocorticography to guide tumor resection was not performed. Patients with biopsy only were included, because although without therapeutic intent, it results in alteration of cerebral neurophysiology and seizure risk. We intended to reflect a patient population that is routinely seen in a neurooncology or epilepsy practice and provide some guidelines for treatment. All patients had a minimum of one year of followup, with a median follow up of 3.8 years and range between 1 and 20 years. All seizure data and outcomes were reviewed by an epileptologist (BCJ). Tumor data collected included date of diagnosis, pathological diagnosis, brain location, type of surgery, cytogenetic status (1p and 19q), radiotherapy, chemotherapy, chemotherapeutic agents, tumor progression, and survival. Cytogenetic status was determined only in patients with an oligodendroglioma component and was not available in all patients. Pathologic diagnosis was independently performed without knowledge of seizure status or prognosis.
Significant tumor growth was defined as an increase in tumor size as evidenced by MRI imaging. Significant tumor growth was defined as a 25% increase in the area measured by perpendicular diameters of the tumor on T2 weighted sequences, which equates to a clinically meaningful progression that in clinical practice would warrant further intervention.
Seizure data included the number and type of seizures the patient experienced before tumor surgery, during the perioperative period (up to 2 weeks after tumor surgery), and more than 2 weeks after tumor surgery. Seizures were classified as generalized tonic-clonic, focal with loss of consciousness, or focal without loss of consciousness. Seizures outcome was assessed using Engel's classification at last follow-up. 8 For patients who developed seizures after surgery, the time of first seizure was used as the starting point for the Engel classification. Although Engel's classification was established for seizure outcome after epilepsy surgery, it is frequently also used to determine seizure outcome after other interventions. 1 Patients who did not experience any seizures before or after surgery were classified as having no seizures ever. Postoperative EEG was not consistently obtained to allow meaningful data analysis. All available information for each patient was entered into a standardized database. The study was reviewed and approved by the Dartmouth College Committee for the Protection of Human Subjects.
Statistical analysis
Two sets of analyses were carried out. First we investigated the predictor variable for seizures at presentation prior to tumor surgery. Second we investigated the predictors for seizure freedom post surgery. Parameters including tumor location, tumor type, use of antiepileptic drugs prior to surgery, length of follow-up, chemotherapy or radiation therapy, gender, history of generalized tonic-clonic seizures and age were analyzed using univariable models and multivariable regression. Additional univariate analysis was performed to compare the grade II tumor pathology to other pathologies. Kaplan-Meier analysis was employed to analyze factors that influenced whether a patient had a least one seizure in the year prior to their last follow-up. Statistical analyses were carried out in SPSS (version 18, Chicago, IL).
Results

Patient population and tumor characteristics
The demographic characteristics of the 73 patients identified are displayed in Table 1 . Besides age there was no significant difference between grade II tumors and other pathologies. Tumor type, tumor location, and type of treatment are shown in Table 2 . Fig. 1 shows the breakdown of seizure occurrence in the 73 patients. Of the 54 (74.0%) patients who had a seizure ever, 46 (85.2%) experienced at least one seizure before their first surgery and pathologic diagnosis, 5 (9.2%) in the perioperative period and 3 (5.6%) after more than 2 weeks after first tumor surgery. Twentyseven tumors were tested for deletion of 1p or 19q and the results are summarized in Table 2 .
Tumor surgery
Initial surgical procedures are listed in Table 2 . Three of the 15 patients who had an initial biopsy had a resection within three month and are included in the resection groups. Patients with other pathologies were more likely to have had a complete resection at initial surgery than patients with grade II tumors (p = 0.018). Thirty-two patients (43.8%) had significant tumor growth during the follow-up period; there were 23/46 (50%) patients in the grade II glioma patients that had significant tumor growth and 9/27 (33%) patients with other pathologies who had significant tumor growth (p > 0.05). 21 had additional tumor related surgical procedures. Of the 21 who had additional surgery, one patient had a biopsy, 6 patients had a partial resection, and 14 had a total resection. Six patients had a third surgery because of significant tumor growth. One had a biopsy and five had further resections.
Temporal profile and characteristics of seizures
There were 46 patients with a first seizure preceding any surgical intervention for the brain tumor. Univariable analysis of seizure occurrence revealed that only tumor location (p = 0.034) and tumor pathology (p = 0.019) are significantly correlated with Thirty-five of 46 patients with pre-operative seizures (74.1%) had seizures after their first surgery. Twenty-four (52.3%) were seizure free at last follow-up. Tumor pathology, cytogenetic status, age at diagnosis, type of first seizure and tumor location were not significant predictors of seizure freedom at last follow-up. Grade II gliomas were not significantly different from other pathologies in terms of seizure outcome (Table 3) , but were more likely than pilocytic astrocytomas and ependymoma, to present with seizures.
Seizure outcome
Eight (29.6%) of 27 patients who had no seizures before their initial surgery experienced seizures; 5 had their first seizure in the perioperative period (<2 weeks) and 3 more than 2 weeks after tumor surgery. Two of the five patients with perioperative seizures were on prophylactic AEDs. Postoperative seizure onset apart from the perioperative period occurred in the first post-surgical year for two patients and in the third year after surgery in one patient. Seizure onset was associated with significant tumor growth in two patients and was not associated with significant tumor growth in the remaining one.
Twenty-two patients of 46 with pre-surgical seizures had an initial total resection. Sixteen (72.7%) continued to have seizures, but twelve of 16 (75.0%) became eventually seizure free during their last year of follow-up. Only 5 of 22 patients (22.7%) patients who had total resection and post-surgical seizures also had tumor progression. Thirteen of 46 patients with pre-surgical seizures had a partial resection as their first surgery. Ten of the 13 (76.9%) had at least one seizure post-operatively. Six of the 10 (60%) were seizure free at last follow-up. Total or partial resection did not influence seizure outcome (p > 0.05) in a regression model, that corrected for tumor pathology as well as in a Chi-square analysis that compared between the grade II gliomas and other pathologies.
Of the 40 patients who had seizures after initial tumor surgery outside of the perioperative period, 23 (57.5%) were seizure-free for at least one year during the post-surgical follow-up period. Thirteen (56.5%) of these patients had recurrent post-surgical seizures after at least one year of seizure freedom. Recurrence of post-surgical seizures occurred in the same year as significant tumor growth was noted in 7 (53.8%) of the 13 patients.
Seven (63.6%) of the 11 patients who were considered to have chronic epilepsy had at least one seizure after their first surgery for the tumor. Five (45.5%) were seizure free at last follow-up. There was no correlation between a diagnosis of chronic epilepsy and seizure outcome at last follow-up.
Significant tumor growth occurred in 32 (43.8%) of 73 patients in this study. Nineteen (59.4%) of the patients who had significant tumor growth were seizure free at last follow up. There was no correlation between significant tumor growth, pathology and seizure outcome at last follow-up (Fig. 1B) .
Chemotherapy and radiation therapy had a positive effect on seizures in a Kaplan-Meier analysis (Fig. 2) . Patients with presurgical seizures who had radiation or chemotherapy were less likely to have seizures at last follow-up than patients who did not (radiation: p = 0.02, chemotherapy: p = 0.03). The Kaplan-Meier analyses for all other factors (age, gender, tumor pathology, tumor location, cytogenetic status) were not significant in terms of seizure outcome after surgery.
All 54 patients with seizures received AED; 44 patients were still receiving medication at last follow-up. For 14 patients, AEDs were discontinued on clinical grounds (no further seizures). Eight of these patients had both pre-and post-surgical seizures, three had pre-surgical seizures only, two had perioperative seizures only, and one had post-surgical seizures only. Of these 14 patients, 10 (71.4%) had no further seizures, while 4 (28.6%) patients experienced a seizure after discontinuing the medication. In three of these four patients, the recurrence of seizures after discontinuing AED was associated with tumor progression. Patients with perioperative seizures who discontinued AED during the first year after surgery had no further seizures. Of the other 10 patients who discontinued AED, all were seizure free while taking AED for 1-4 years before tapering. Due to multiple medications and dosages used, further statistical analysis regarding which AED is more effective was not possible.
Two patients in this study received a vagal nerve stimulator implant, which reduced their seizure frequency by more than 50%. Both of these patients previously underwent previous tumor resections. Five patients whose seizures continued after tumor resection subsequently underwent a detailed work-up for further epilepsy surgery and had further resections. In four of the five Table 3 Engel classification of outcomes after surgery. Seizure outcome in all patients, in patients with grade II gliomas and other pathologies. There was no significant difference in seizures outcome whether patients had grade II gliomas or other pathologies.
Engel class
All patients (n = 73) Grade II gliomas n = 46
Other pathologies n = 27 patients, subdural grids were placed for seizure localization. Four patients had an Engel class I outcome after epilepsy surgery and one patient had a class IV outcome due to tumor progression.
Discussion
Seizures and their management have a major impact on the quality of life of patients with low grade tumors. In this study we identified pathology as the only factor associated with seizures at presentation. Once seizures were established the seizure outcome was independent of underlying pathology with eventual seizure freedom achieved in about 50% of patients. Pathology did not influence final seizure outcome. Patient with pilocytic astrocytomas and ependymomas are less likely to present with seizures, however once seizures are established, the seizure prognosis was not any different than in grade II gliomas. Patients who had seizures preceding tumor surgery were more likely to have postsurgical seizures, although, interestingly, the type of resection, increase in tumor size and the number of preoperative seizures did not correlate with seizure outcome.
Some studies report more favorable seizure outcomes for patients who underwent gross-total resection of a low-grade glioma, 1,9,10 but, as in our study, others have not observed correlation between extent of resection and seizure outcome.
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The pathophysiologic mechanism for seizure generation may be dependent on other factors such as involved neuronal networks or blood-brain barrier dysfunction and independent on extent of tumor removal. Seizure outcome in our study is less favorable than in other studies, 1, 4, 10, 12 which is likely a function of our prolonged follow up time and patient selection. Our study mirrors a population routinely seen in a neuro-oncology clinic and does not only focus on patients with intractable epilepsy, 7,12 certain tumor locations 6 or non-progressive tumors. 7, 12 Previous studies focused on seizures at presentation, included a wide variety of tumors including glioblastoma, [13] [14] [15] or limited postsurgical follow up to twelve months. 16 Our results strengthen the recommendation that prophylactic AED treatment is not indicated for patients with low grade gliomas. 17, 18 In the perioperative period new onset seizures occur in a small number of patients and in most cases they do not recur. Furthermore, patients without seizures before tumor surgery are unlikely to develop seizures unless associated with increase in tumor size. 1, 13 Nevertheless, in clinical practice prophylactic AED are frequently continued for prolonged periods of time. 19 We identified that treatment with radiation and chemotherapy has a positive effect in the control of seizures. Our study accounts for currently used chemotherapy agents, like temozolomide, and more targeted radiation therapy techniques compared to older studies. 10, 7 A positive effect of radiation on seizures was suggested in nine patients by Chalifoux and Elisevich 20 and was confirmed by our study. Pace et al. reported a ''relevant'' effect of chemotherapy on seizure control in 31 patients treated effectively with temozolomide. 21 A very recent cohort study suggested a similar positive effect of temozolomide. 22 It is possible that chemotherapy and radiation have a modulatory effect that affects seizure generation. Peritumoral processes may play a significant role in seizure generation that may be influenced by radiation or chemotherapy. 23 The small sample size prevents our study from providing a definite recommendation when to discontinue AED treatment in the patient with low grade tumors. Patients who had been seizure free for prolonged periods of time were offered to discontinue AED. Most of them did not have recurrent seizures apart from the setting of tumor recurrence. It seems clinically appropriate to discontinue AED in patients with pre-operative seizures who do not have seizures for more than 2 years after tumor surgery or treatment with radiation and chemotherapy and without evidence of significant increase in tumor size. Nonetheless, approximately 25% of those patients will have a recurrent seizure, most often associated with a significant increase in tumor size. Unfortunately due to various AED regimens, further analysis was not possible to assess efficacy of AED or establish differences between AED. Future controlled studies are needed to establish guidelines for discontinuing AED and to determine efficacy in low-grade glioma patients.
Although epilepsy surgery was only performed on five patients in our study, it led to improved seizure outcome for four of these patients. This indicates that epilepsy surgery should be considered Fig. 2 . Kaplan-Meier analysis of seizure freedom during follow-up from time of surgery for 46 pre-surgical seizure patients who underwent radiation therapy or chemotherapy compared to patients who did not. All patients in our study who did not undergo chemotherapy had less than 10 years of follow-up so the ''no chemotherapy'' line is shorter than the ''chemotherapy'' line on the graph. This was not a function of survival.
as a possible option for treating refractory seizures in low-grade tumor patients. Neuro-oncologists and epileptologists should be encouraged to cooperate to not only limit tumor growth but also to treat seizures which can significantly impair quality of life. In a previous study, epilepsy surgery was successful in 12 of 14 patients with temporal lobe tumors and medically refractory epilepsy, 24 however inclusion criteria for tumors differ in neuro-oncology and epilepsy-related studies.
In conclusion, the greatest risk factor for seizures in low-grade tumors is previous seizures. Pathology does not influence seizure outcome once seizures are established. Prophylactic AEDs are not indicated. Chemotherapy and radiation therapy have a positive effect on seizures, but further studies are needed to examine the interactions of AED and chemotherapy. In addition, controlled studies are needed to examine when it is appropriate to discontinue AEDs and which AED is most efficient.
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